What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Cancer research, Radiation therapy, Pathology, Immunology and Apoptosis.
His Cancer research research is multidisciplinary, relying on both Paclitaxel, Chemotherapy, Ratón, Radioresistance and Receptor.
His Radiation therapy research integrates issues from Cell cycle, Cancer and In vivo.
The concepts of his Pathology study are interwoven with issues in Tumor necrosis factor alpha, Cell culture, Epidermal growth factor, Radiosensitivity and Epidermal growth factor receptor.
His work carried out in the field of Immunology brings together such families of science as Clinical trial, Animal studies and Therapeutic index.
He combines subjects such as Endocrinology and Oncology with his study of Internal medicine.
His most cited work include:
- Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. (1000 citations)
- In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. (477 citations)
- Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase (444 citations)
What are the main themes of his work throughout his whole career to date?
Luka Milas mostly deals with Cancer research, Radiation therapy, Pathology, Internal medicine and Chemotherapy.
His work deals with themes such as Radiosensitivity, Apoptosis, Paclitaxel, Immunology and In vivo, which intersect with Cancer research.
His Radiation therapy research is multidisciplinary, incorporating perspectives in Cancer, Epidermal growth factor receptor, Clinical trial, Therapeutic index and Pharmacology.
He has researched Pathology in several fields, including Lung and Ratón.
His research investigates the connection with Internal medicine and areas like Oncology which intersect with concerns in Head and neck cancer.
His Chemotherapy research incorporates elements of Angiogenesis and Immunotherapy.
He most often published in these fields:
- Cancer research (44.07%)
- Radiation therapy (41.11%)
- Pathology (31.85%)
What were the highlights of his more recent work (between 2007-2014)?
- Cancer research (44.07%)
- Radiation therapy (41.11%)
- Cancer (18.89%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Radiation therapy, Cancer, Radiosensitivity and Internal medicine.
His Cancer research study combines topics in areas such as Epidermal growth factor receptor, Head and neck squamous-cell carcinoma, Immunology, Pathology and Radioresistance.
His Radiation therapy study integrates concerns from other disciplines, such as Tumor bed, Clinical trial, Cancer stem cell, Tumor growth and Carcinoma.
His Cancer research includes elements of Poly ADP ribose polymerase, Poly Polymerase Inhibitor, Stem cell and In vivo.
His research in Radiosensitivity intersects with topics in Cell, Cell cycle, Apoptosis, Cell culture and DNA repair.
His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine.
Between 2007 and 2014, his most popular works were:
- Single Nucleotide Polymorphism at rs1982073:T869C of the TGFβ1 Gene Is Associated With the Risk of Radiation Pneumonitis in Patients With Non–Small-Cell Lung Cancer Treated With Definitive Radiotherapy (132 citations)
- Receptor signaling as a regulatory mechanism of DNA repair (84 citations)
- Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. (66 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Luka Milas focuses on Cancer research, DNA repair, Cancer cell, Radiosensitivity and Cancer.
His biological study spans a wide range of topics, including In vivo, DNA damage and Epidermal growth factor receptor.
His DNA repair research is multidisciplinary, incorporating elements of Cell and Cell biology.
His Radiosensitivity research incorporates themes from Clonogenic assay and Pathology.
His research integrates issues of Radiation therapy and Programmed cell death in his study of Cancer stem cell.
His study in Radiation therapy is interdisciplinary in nature, drawing from both Clinical trial, Immunology and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
